These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 25836641)

  • 21. CD4+CXCR4+ T cells as a novel prognostic biomarker in patients with idiopathic inflammatory myopathy-associated interstitial lung disease.
    Wang K; Zhao J; Chen Z; Li T; Tan X; Zheng Y; Gu L; Guo L; Sun F; Wang H; Li J; Wang X; Riemekasten G; Ye S
    Rheumatology (Oxford); 2019 Mar; 58(3):511-521. PubMed ID: 30508148
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pulmonary complications of inflammatory myopathy.
    Ascherman DP
    Curr Rheumatol Rep; 2002 Oct; 4(5):409-14. PubMed ID: 12217246
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Interstitial lung disease in patients with polymyositis and dermatomyositis--report of three cases].
    Bartosiewicz M; Siemion-Szcześniak I; Sobiecka M; Wyrostkiewicz D; Radwan-Röhrenschef P; Lewandowska K; Langfort R; Oniszh K; Franczuk M; Kuś J
    Pneumonol Alergol Pol; 2013; 81(6):556-66. PubMed ID: 24142786
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Serum levels of galectin-3 in idiopathic inflammatory myopathies: a potential biomarker of disease activity.
    Watanabe E; Kato K; Gono T; Chiba E; Terai C; Kotake S
    Rheumatology (Oxford); 2021 Jan; 60(1):322-332. PubMed ID: 32770187
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical manifestations and outcome of anti-PL7 positive patients with antisynthetase syndrome.
    Marie I; Josse S; Decaux O; Diot E; Landron C; Roblot P; Jouneau S; Hatron PY; Hachulla E; Vittecoq O; Menard JF; Jouen F; Dominique S
    Eur J Intern Med; 2013 Jul; 24(5):474-9. PubMed ID: 23375620
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [The antisynthetase syndrome: a cause of rapidly progressive interstitial lung disease].
    Jordan Greco AS; Métrailler JC; Dayer E
    Rev Med Suisse; 2007 Nov; 3(134):2675-6, 2679-81. PubMed ID: 18159702
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Antisynthetase syndrome].
    Gran JT
    Tidsskr Nor Laegeforen; 2002 Sep; 122(23):2270-2. PubMed ID: 12448266
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Diagnosis and Management of Myositis-Associated Lung Disease.
    Hallowell RW; Danoff SK
    Chest; 2023 Jun; 163(6):1476-1491. PubMed ID: 36764512
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Interstitial lung disease in polymyositis and dermatomyositis: clinical course and response to treatment.
    Schnabel A; Reuter M; Biederer J; Richter C; Gross WL
    Semin Arthritis Rheum; 2003 Apr; 32(5):273-84. PubMed ID: 12701038
    [TBL] [Abstract][Full Text] [Related]  

  • 30. New paradigm in the treatment of myositis-associated interstitial lung disease.
    Gono T; Kuwana M
    Expert Rev Respir Med; 2023 May; 17(5):397-411. PubMed ID: 37199348
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Association of anti-nuclear matrix protein 2 antibody with complications in patients with idiopathic inflammatory myopathies: A meta-analysis of 20 cohorts.
    Zhong L; Yu Z; Song H
    Clin Immunol; 2019 Jan; 198():11-18. PubMed ID: 30445156
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Myositis in clinical practice-relevance of new antibodies.
    Moghadam-Kia S; Aggarwal R; Oddis CV
    Best Pract Res Clin Rheumatol; 2018 Dec; 32(6):887-901. PubMed ID: 31427061
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Interstitial lung disease associated with the idiopathic inflammatory myopathies: what progress has been made in the past 35 years?
    Connors GR; Christopher-Stine L; Oddis CV; Danoff SK
    Chest; 2010 Dec; 138(6):1464-74. PubMed ID: 21138882
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Idiopathic inflammatory myopathy with diffuse alveolar damage.
    Lee CS; Chen TL; Tzen CY; Lin FJ; Peng MJ; Wu CL; Chen PJ
    Clin Rheumatol; 2002 Sep; 21(5):391-6. PubMed ID: 12223988
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intravenous Immunoglobulin as Potential Adjunct Therapy for Interstitial Lung Disease.
    Hallowell RW; Amariei D; Danoff SK
    Ann Am Thorac Soc; 2016 Oct; 13(10):1682-1688. PubMed ID: 27482830
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Idiopathic inflammatory myositis-associated interstitial lung disease: ethnicity differences and lung function trends in a British cohort.
    Chua F; Higton AM; Colebatch AN; O'Reilly K; Grubnic S; Vlahos I; Edwards CJ; Kiely PD
    Rheumatology (Oxford); 2012 Oct; 51(10):1870-6. PubMed ID: 22763991
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Polymyositis/dermatomyositis and interstitial lung disease: a new therapeutic approach with T-cell-specific immunosuppressants.
    Takada K; Nagasaka K; Miyasaka N
    Autoimmunity; 2005 Aug; 38(5):383-92. PubMed ID: 16227154
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Antisynthetase syndrome: a report of four cases and literature review].
    Frikha F; Saidi N; Snoussi M; Ben Salah R; Ben Ayed M; Daoud E; Hentati Y; Makni S; Mnif Z; Boudawara T; Masmoudi H; Bahloul Z
    Rev Pneumol Clin; 2012 Dec; 68(6):351-60. PubMed ID: 23062471
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Classification, diagnosis, and management of idiopathic inflammatory myopathies.
    Lazarou IN; Guerne PA
    J Rheumatol; 2013 May; 40(5):550-64. PubMed ID: 23504386
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Interstitial lung disease and cryoglobulinemia in polymyositis.
    Lambie PB; Quismorio FP
    J Rheumatol; 1991 Mar; 18(3):468-9. PubMed ID: 1856818
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.